Erika Yamashita

Erika Yamashita

Auto-generated profile, based on publicly available information

Erika Yamashita

Department of Immunology and Cell Biology, Graduate School of Medicine & Frontier Biosciences, Osaka University, Osaka, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Nature
Verified
Journal Article
Closed access
PDF file
YMYu Miyamoto
Yu Miyamoto
JKJunichi Kikuta
Junichi Kikuta
TMTakahiro Matsui
Takahiro Matsui
THTetsuo Hasegawa
Tetsuo Hasegawa
KFKentaro Fujii
Kentaro Fujii
MIMasaru Ishii
Masaru Ishii

24 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MUMaki Uenaka
Maki Uenaka
EYErika Yamashita
Erika Yamashita
JKJunichi Kikuta
Junichi Kikuta
AMAkito Morimoto
Akito Morimoto
TATomoka Ao
Tomoka Ao
MIMasaru Ishii
Masaru Ishii
Bone metabolism is regulated by the cooperative activity between bone-forming osteoblasts and bone-resorbing osteoclasts. However, the mechanisms mediating the switch between the osteoblastic and osteoclastic phases have not been fully elucidated. Here, we identify a specific subset of mature osteoblast-derived extracellular vesicles that inhibit bone formation and enhance osteoclastogenesis. Intravital imaging reveals that mature osteoblasts secrete and capture extracellular vesicles, referred to as small osteoblast vesicles (SOVs). Co-culture experiments demonstrate that SOVs suppress osteoblast differentiation and enhance the expression of receptor activator of NF-κB ligand, thereby inducing osteoclast differentiation. We also elucidate that the SOV-enriched microRNA miR-143 inhibits Runt-related transcription factor 2, a master regulator of osteoblastogenesis, by targeting the mRNA expression of its dimerization partner, core-binding factor β. In summary, we identify SOVs as a mode of cell-to-cell communication, controlling the dynamic transition from bone-forming to bone-resorbing phases in vivo.

1 September 2017 in Science Advances
Verified
Journal Article
Open access
PDF file
MTMamoru Takizawa
Mamoru Takizawa
TATakao Arimori
Takao Arimori
YTYukimasa Taniguchi
Yukimasa Taniguchi
YKYu Kitago
Yu Kitago
EYErika Yamashita
Erika Yamashita
KSKiyotoshi Sekiguchi
Kiyotoshi Sekiguchi
The Glu residue in the laminin γ-tail forms a bipartite integrin binding site with three globular domains of the α chain.

10 August 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
THTetsuo Hasegawa
Tetsuo Hasegawa
JKJunichi Kikuta
Junichi Kikuta
TSTakao Sudo
Takao Sudo
EYErika Yamashita
Erika Yamashita
SSShigeto Seno
Shigeto Seno
MIMasaru Ishii
Masaru Ishii
There have been many attempts to visualize the inflamed joints using multiphoton microscopy. However, due to the hypervascular and multilayered structure of the inflamed synovium, intravital imaging of the deep synovial tissue has been difficult. Here, we established original intravital imaging systems to visualize synovial tissue and pathological osteoclasts at the pannus–bone interface using multiphoton microscopy. Combined with fluorescence-labeling of CTLA-4 Ig, a biological agent used for the treatment of rheumatoid arthritis, we identified that CTLA-4 Ig was distributed predominantly within the inflamed synovium and bound to CX3CR1+macrophages and CD140a+fibroblasts 6 h after injection, but not to mature osteoclasts. Intravital imaging of blood and lymphatic vessels in the inflamed synovium further showed that extravasated CTLA-4 Ig was immediately drained through lymphatic vessels under acute arthritic conditions, but the drainage activity was retarded under chronic conditions. These results indicate that this intravital synovial imaging system can serve as a platform for exploring the dynamics of immune cells, osteoclasts, and biological agents within the synovial microenvironment in vivo.

3 October 2025 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
ADAbhishek Dubey
Abhishek Dubey
EYErika Yamashita
Erika Yamashita
BSBiljana Stangeland
Biljana Stangeland
IAImane Abbas
Imane Abbas
DFDavid Fooksman
David Fooksman
JBJinan Behnan
Jinan Behnan
The skull marrow niche has recently been identified as a reservoir that supplies the brain with monocytes and neutrophils in the context of disease and injury, but its role in brain cancers remains unknown. Here we show that glioblastoma, the most malignant type of brain tumor, induces calvarial bone abnormalities in murine models and patients with glioblastoma, altering osteoclast activities and increasing the number of skull channels in mice. Single-cell RNA sequencing revealed glioblastoma-mediated alterations in the immune landscape of skull marrow and femoral bone marrow, including expansion of neutrophils and deterioration of various B cell subsets. In vivo inhibition of bone resorption reduced bone abnormalities, but promoted tumor progression in mesenchymal subtype tumors. This also abolished the survival benefit of the checkpoint inhibitor anti-PD-L1, by reducing activated T cell and increasing inflammatory neutrophil numbers. Together, these data provide insight into how brain tumors affect skull bone and the immune environment.

6 July 2020 in Inflammation and Regeneration
Verified
Journal Article
Open access
PDF file
MMMaho Morimatsu
Maho Morimatsu
EYErika Yamashita
Erika Yamashita
SSShigeto Seno
Shigeto Seno
TSTakao Sudo
Takao Sudo
JKJunichi Kikuta
Junichi Kikuta
MIMasaru Ishii
Masaru Ishii
Background: Dormant chemotherapy-resistant leukemia cells can survive for an extended period before relapse. Nevertheless, the mechanisms underlying the development of chemoresistance in vivo remain unclear. Methods: Using intravital bone imaging, we characterized the behavior of murine acute myeloid leukemia (AML) cells (C1498) in the bone marrow before and after chemotherapy with cytarabine. Results: Proliferative C1498 cells exhibited high motility in the bone marrow. Cytarabine treatment impaired the motility of residual C1498 cells. However, C1498 cells regained their migration potential after relapse. RNA sequencing revealed that cytarabine treatment promoted MRTF-SRF pathway activation. MRTF inhibition using CCG-203971 augmented the anti-tumor effects of chemotherapy in our AML mouse model, as well as suppressed the migration of chemoresistant C1498 cells. Conclusions: These results provide novel insight into the role of cell migration arrest on the development of chemoresistance in AML, as well as provide a strong rationale for the modulation of cellular motility as a therapeutic target for refractory AML.